Corrigendum to “Master protocol trial design for technical feasibility of MR-guided radiotherapy” [Radiother. Oncol. 166 (2022) 33–36]

After publication of the abovementioned article, the authors regret that an inaccuracy has been noticed. In the Method section, the prospective cohort study of the MR-Linac consortium is described (MOMENTUM study, clinicaltrials.gov NCT04075305). Participants of this cohort provide informed consent for collection of technical and clinical data relating to their MR-Linac treatment. It was stated that participants can consent separately to share data to MR-Linac partners, Elekta and Philips Healthcare. This wrongly suggests that their data is shared with both of these partners. In fact, participants are asked if their data can be shared with commercial MR-Linac partners, such as Elekta. This has now been corrected in the online version. Master protocol trial design for technical feasibility of MR-guided radiotherapyRadiotherapy and OncologyVol. 166PreviewThe master protocol trial design aims to increase efficiency in terms of trial infrastructure and protocol administration which may accelerate development of (technical) innovations in radiation oncology. A master protocol to study feasibility of techniques/software for MR-guided adaptive radiotherapy with the MR-Linac is described and discussed. Full-Text PDF